These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7577039)

  • 1. Multidrug resistance and the role of P-glycoprotein knockout mice.
    Schinkel AH; Mol CA; Wagenaar E; van Deemter L; Smit JJ; Borst P
    Eur J Cancer; 1995; 31A(7-8):1295-8. PubMed ID: 7577039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
    van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
    J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
    Schinkel AH; Mayer U; Wagenaar E; Mol CA; van Deemter L; Smit JJ; van der Valk MA; Voordouw AC; Spits H; van Tellingen O; Zijlmans JM; Fibbe WE; Borst P
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):4028-33. PubMed ID: 9108099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development.
    Chen C; Liu X; Smith BJ
    Curr Drug Metab; 2003 Aug; 4(4):272-91. PubMed ID: 12871045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of mdr1a p-glycoprotein gene results in dysfunction of blood-inner ear barrier in mice.
    Zhang ZJ; Saito T; Kimura Y; Sugimoto C; Ohtsubo T; Saito H
    Brain Res; 2000 Jan; 852(1):116-26. PubMed ID: 10661503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.
    Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC
    Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.
    Sharom FJ; Yu X; Lu P; Liu R; Chu JW; Szabó K; Müller M; Hose CD; Monks A; Váradi A; Seprôdi J; Sarkadi B
    Biochem Pharmacol; 1999 Aug; 58(4):571-86. PubMed ID: 10413294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of p-glycoprotein--lead identification and optimisation.
    Pleban K; Ecker GF
    Mini Rev Med Chem; 2005 Feb; 5(2):153-63. PubMed ID: 15720285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells.
    Zhu CY; Lv YP; Yan DF; Gao FL
    Asian Pac J Cancer Prev; 2013; 14(11):6757-60. PubMed ID: 24377601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological insights from P-glycoprotein knockout mice.
    Schinkel AH
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):9-13. PubMed ID: 9476142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
    Borst P; Schinkel AH
    Eur J Cancer; 1996 Jun; 32A(6):985-90. PubMed ID: 8763339
    [No Abstract]   [Full Text] [Related]  

  • 16. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein and multidrug resistance.
    Gottesman MM; Pastan I; Ambudkar SV
    Curr Opin Genet Dev; 1996 Oct; 6(5):610-7. PubMed ID: 8939727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
    Schinkel AH; Smit JJ; van Tellingen O; Beijnen JH; Wagenaar E; van Deemter L; Mol CA; van der Valk MA; Robanus-Maandag EC; te Riele HP
    Cell; 1994 May; 77(4):491-502. PubMed ID: 7910522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas.
    Stein U; Shoemaker RH; Schlag PM
    Eur J Cancer; 1996 Jan; 32A(1):86-92. PubMed ID: 8695249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.